Cobenfy’s 2024 approval added a muscarinic-based option for adults with schizophrenia. Here is what the trials and current safety labeling can—and cannot—tell patients.
An approved option for adults
FDA approved Cobenfy on September 26, 2024, for schizophrenia in adults. The FDA approval package records that date and indication. This is an explanation of an existing approval, not a new announcement.
Cobenfy combines xanomeline and trospium chloride in an oral capsule. The prescribing information, revised January 2026, identifies xanomeline as a muscarinic agonist and trospium as a muscarinic antagonist. In plain language, the components affect signaling through muscarinic receptors. The label says the mechanism of action in schizophrenia is unclear, but efficacy is thought to involve xanomeline’s activity at M1 and M4 receptors. A proposed mechanism is not proof of a particular outcome for an individual.
What supported FDA approval
The FDA Drug Trials Snapshot describes two clinical trials involving adults with schizophrenia. The prescribing information describes two five-week, randomized, double-blind, placebo-controlled studies. Researchers assessed changes in schizophrenia symptoms using the Positive and Negative Syndrome Scale, or PANSS.
Cobenfy improved the trial’s symptom measure compared with placebo. That is different from demonstrating superiority over another active medication: these studies did not compare it head-to-head with every established antipsychotic. Their short duration also matters when interpreting what the original approval evidence tells us about longer-term care.
Safety is part of the discussion
The January 2026 prescribing information does not carry a boxed warning. That does not mean the medicine is risk-free. It lists contraindications including urinary retention, gastric retention, moderate or severe liver impairment, untreated narrow-angle glaucoma, and certain hypersensitivity reactions. It is not recommended for moderate or severe kidney impairment or mild liver impairment.
The label calls for liver enzyme and bilirubin assessment before treatment and as clinically indicated, and heart rate assessment before and during treatment. Warnings include urinary retention, biliary disease and liver injury, decreased gastrointestinal movement, angioedema, and increased heart rate. Common adverse reactions include nausea, indigestion, constipation, vomiting, and other gastrointestinal symptoms. A prescriber needs a full medication and health history to assess these risks and interactions.
What this means for treatment choices
Our editorial interpretation is that this adds a distinct option to a clinician-led discussion—not that it replaces all existing medications or cures schizophrenia. The approval discussed here is for adults with schizophrenia; it should not be presented as approval for children or other psychiatric conditions.
People already taking medication should discuss changes with their prescriber rather than switching or stopping on their own. Ask how the expected benefits compare with your current care, which health conditions or medicines affect eligibility, what monitoring is needed, and whether your plan covers the prescription. We have not established a universal patient cost or coverage rule.
Explore our condition guides or find a psychiatric clinic to discuss medication options and ongoing support.
Source check: October 13, 2026. Written and reviewed by the Psychiatry Clinics editorial team against the FDA approval package, FDA trial summary, and current prescribing information.
This page is informational and is not medical advice.
More reporting on treatment updates.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.